The potential renoprotective effect of Raloxifene in renal ischemia-reperfusion injury in a male rat model.
| Autor: | Ali RAH; Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Kufa, Iraq., Altimimi M; Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Kufa, Iraq., Hadi NR; Department of Pharmacology and Therapeutics, Faculty of Medicine, University of Kufa, Kufa, Iraq. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of medicine and life [J Med Life] 2023 Aug; Vol. 16 (8), pp. 1274-1281. |
| DOI: | 10.25122/jml-2023-0100 |
| Abstrakt: | Renal ischemia-reperfusion injury is caused by a temporary reduction in oxygen-carrying blood flow to the kidney, followed by reperfusion. During ischemia, kidney tissue damage induces overproduction of reactive oxygen species, which produces oxidative stress. The blood flow restoration during the reperfusion period causes further production of reactive oxygen species that ends with apoptosis and cell death. This study aimed to investigate the potential renoprotective effects of Raloxifene on bilateral renal ischemia-reperfusion injury in rats by looking into kidney function biomarkers, urea and creatinine, inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β). Additionally, antioxidant markers such as total antioxidant capacity (TAC) and the pro-apoptotic marker caspase-3 were assessed. Histopathological scores were also employed for evaluation. Our experimental design involved 20 rats divided into four groups: the sham group underwent median laparotomy without ischemia induction, the control group experienced bilateral renal ischemia for 30 minutes followed by 2 hours of reperfusion, the vehicle group received pretreatment with a mixture of corn oil and dimethyl sulfoxide (DMSO) before ischemia induction, and the Raloxifene-treated group was administered Raloxifene at a dose of 10 mg/kg before ischemia induction, followed by ischemia-reperfusion. Urea and creatinine, TNF-α, IL-1β, and caspase-3 in the Raloxifene group were significantly lower compared to the control and vehicle groups. On the other hand, TAC levels in the Raloxifene group were significantly higher than in the control and vehicle groups. This study concluded that Raloxifene had a renoprotective impact via multiple actions as an anti-inflammatory, anti-apoptotic, and antioxidant agent. Competing Interests: The authors declare no conflict of interest. (©2023 JOURNAL of MEDICINE and LIFE.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|